Efficacy of boceprevir, an NS3 protease inhibitor, in combination withpeginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Antonio Craxi

Efficacy of boceprevir, an NS3 protease inhibitor, in combination withpeginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article › peer review

Lingua originale	English
Numero di pagine	12
Rivista	The Lancet
Volume	376
Stato di pubblicazione	Published - 2010

Altri file e collegamenti

OA Link

Cita questo

@article{f4220ff964f946e09fd4f974a11cb550,

title = "Efficacy of boceprevir, an NS3 protease inhibitor, in combination withpeginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial",

author = "Antonio Craxi",

year = "2010",

language = "English",

volume = "376",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Efficacy of boceprevir, an NS3 protease inhibitor, in combination withpeginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

AU - Craxi, Antonio

PY - 2010

Y1 - 2010

UR - http://hdl.handle.net/10447/73859

M3 - Article

VL - 376

JO - The Lancet

JF - The Lancet

SN - 0140-6736

ER -